Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17812871 | 0.85 | NOTUM (0.41) | NOTUMALDH1A1KDM4EHPGD | |
| SCHEMBL22214045 | 0.70 | CNR2 (0.33) | ALDH1A1 | |
| SCHEMBL9769352 | 0.69 | ADRB2 (0.33) | ALDH1A1KDM4EHPGD | |
| SCHEMBL19788241 | 0.69 | — | — | |
| SCHEMBL9290949 | 0.67 | HTT (0.30) | — | |
| SCHEMBL9769173 | 0.66 | — | — | |
| SCHEMBL9769266 | 0.66 | ADRB2 (0.35) | — | |
| SCHEMBL9769296 | 0.64 | ADRB2 (0.44) | KDM4E | |
| SCHEMBL10584351 | 0.64 | ADRB2 (0.44) | KDM4E | |
| SCHEMBL2857448 | 0.63 | ESR1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239876-B2 | Triaza-spirodecanones as DDR1 inhibitors | HOFFMAN LA-ROCHE INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180148450-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN LA-ROCHE INC. (US) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148450-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | DDR1, DDR2, DDRGK1 | NOTUM 4733/4885ALDH1A1 1320/4885KDM4E 3174/4885 |
| US-10239876-B2 | Triaza-spirodecanones as DDR1 inhibitors | DDR1, DDR2, DDRGK1 | NOTUM 4733/4885ALDH1A1 1320/4885KDM4E 3174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.